Medicenna Therapeutics (TSE:MDNA) Shares Pass Below Fifty Day Moving Average – Here’s Why

Medicenna Therapeutics Corp. (TSE:MDNA) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$0.39 and traded as low as C$0.38. Medicenna Therapeutics shares last traded at C$0.39, with a volume of 41,383 shares changing hands.

Medicenna Therapeutics Trading Down 3.8%

The firm’s 50 day simple moving average is C$0.39 and its 200-day simple moving average is C$0.60. The company has a market capitalization of C$34.61 million, a PE ratio of -1.70 and a beta of 2.97. The company has a quick ratio of 4.65, a current ratio of 1.52 and a debt-to-equity ratio of 4.79.

Medicenna Therapeutics (TSE:MDNA) last issued its earnings results on Thursday, June 25th. The company reported C($0.05) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 219.30%. As a group, equities research analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.